Hookipa Biotech announces data showing TheraT turns cold tumours hot
TheraT mediated alarmin release crucial for active immunization in cancer immunotherapy.
Hookipa Biotech has announced publication in Nature Communications of research data in a transgenic mouse model showing how its replicating viral vector platform TheraT delivers potent innate immune activation including key alarmin signals.
Hookipa’s CSO, Professor Daniel D. Pinschewer, of the Division of Experimental Virology, Department of Biomedicine, University of Basel, Switzerland, and senior co-author of the paper, said: “This key research data is the first publication on Hookipa’s platform technology TheraT (also referred to as artLCMV). The paper shows TheraT’s tremendously potent anti-tumour effects and also the underlying molecular mechanism. Eliciting the most potent cytotoxic T cell responses is a crucial step in treating patients with aggressive cancers.”
Hookipa’s TheraT, based on live-attenuated lymphocytic choriomeningitis virus (artLCMV), has been designed to harness the immune system to combat cancer. TheraT works by delivering tumour-associated antigen-specific immunization alongside the release of the alarmin interleukin-33 (IL-33). IL-33 is a key driver of potent and protective CD8+ cytotoxic effector T lymphocytes (CTL), and TheraT is engineered to target stromal cells, which release IL-33 to trigger this alarmin pathway, providing a discriminating feature of TheraT. The Nature Communications paper details experimental work in gene-targeted mice showing triggering of such IL-33 signals provides potent tumor immunotherapy.
Hookipa has an exclusive license to commercially exploit the unique novel cancer immunotherapy platform (TheraT) developed by scientists at the University of Basel and University of Geneva.
Commenting on the publication, Hookipa´s CEO, Mr Jörn Aldag said: “With Hookipa’s novel Vaxwave and TheraT platforms, the Company has a strong technology foundation. This publication in the high impact factor journal Nature Communications is another important milestone on our drive to deliver next-generation cancer immune therapeutics and vaccines to patients. We intend to start clinical development of an HPV+ head and neck cancer program based on TheraT in 2018”.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance